Slide 1: Transforming health through the human microbiome
For personal use only Transforming health through the human microbiome Q1 FY23 Results & Update October 2022 | Authorised for release by the CEO & Chairman ASX: MAP
Slide 2: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its abs
Slide 3: Microba's Commercial Model
Microba’s Commercial Model Global testing services build a proprietary databank driving transformative novel therapies For personal use only Services Databank Therapeutics Proprietary databank Data Insights Health Data Customer Novel Testing Biome Data Therapies Microba provides testing Data-driven
Slide 4: Company Snapshot
Company Snapshot For personal use only Continuous YoY Partnerships with market leaders Large, unique, proprietary revenue growth over incl. SYNLAB (GR:SYAB), microbiome databank 5 years of operations Illumina (NASDAQ: ILMN), Genova Diagnostics, and G42 3 key therapeutic programs World-leading techno
Slide 5: Microbiome Services
For personal use only Microbiome Services Driving global revenues and data growth 5
Slide 6: Expanding network of global distribution partners
Expanding network of global distribution partners Distribution agreements executed with global market leaders to distribute microbiome testing solutions For personal use only powered by Microba’s world leading Analysis Platform technology. Update kit Update kit AU & NZ Europe US Middle East AU New N
Slide 7: Global distribution expansion driving growth post COVID
Global distribution expansion driving growth post COVID For personal use only 10 >20 # Distributors COVID-19 impact Leads 9 8 10 7 Qualified opportunities 6 5 4 5 18 Potential new countries 3 3 3 2 2 4 1 Potential new US distributors 0 FY18 FY19 FY20 FY21 FY22 FY23* *growth expected based on establi
Slide 8: Strategically aligned partners are motivated and ramping up
Strategically aligned partners are motivated and ramping up For personal use only 8
Slide 9: Microbiome Therapeutics
For personal use only Microbiome Therapeutics Developing novel monoclonal microbial cell therapies 9
Slide 10: Repeatable, scalable, data-driven platform discovering novel monoclonal microbial cell therapies
Repeatable, scalable, data-driven platform discovering novel monoclonal microbial cell therapies For personal use only Monoclonal Population Identify AI & Advanced Disease microbial testing groups Biostatistics Models drug lead Healthy Orally administered, healthy Disease human donor derived, monocl
Slide 11: Key milestones upcoming for therapeutic programs
Key milestones upcoming for therapeutic programs For personal use only Inflammatory Bowel Disease Cancer Immunotherapy Autoimmune Diseases PROGRESSING TO PHASE I PRECLINICAL SCREENING Recently Completed Recently Completed Recently Completed Manufacturing scale up Leads discovered Program comme
Slide 12: The start of a microbiome therapeutic revolution
The start of a microbiome therapeutic revolution For personal use only FDA APPROVAL WOULD Q4 CY22 /Q1 CY23 anticipated FDA approval Feacal doner derived enema CLEAR THE PATH TO MARKET drug product FOR LIVE MICROBIOME DRUGS, H1 CY23 A NEW MODALITY. anticipated FDA approval Feacal doner derived oral c
Slide 13: Seres Therapeutics performance as FDA approval edges closer
Seres Therapeutics performance as FDA approval edges closer For personal use only 240% growth over the last 3 months 13
Slide 14: Outlook
For personal use only Outlook 14
Slide 15: Upcoming Milestones for FY23
Upcoming Milestones for FY23 2022 2023 2023 For personal use only OCT – DEC JAN - MAR APR - JUN Services New healthcare product full launch Services SYNLAB country expansion Services New international distribution deals Services New international distribution deals Therapeutics - IBD MAP315 program
Slide 16: Contact
Contact For personal use only Dr Luke Reid Chief Executive Officer luke.reid@microba.com Head Office Level 10, 324 Queen Street Brisbane QLD Australia Pasquale Rombola Laboratory Princess Alexandra Hospital Chairman Woolloongabba QLD Australia pasquale.rombola@microba.com